Please login to the form below

Not currently logged in
Email:
Password:

pegfilgrastim

This page shows the latest pegfilgrastim news and features for those working in and with pharma, biotech and healthcare.

Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars

Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars

These savings derived mainly from trastuzumab and bevacizumab to treat a range of cancers, infliximab for autoimmune diseases, and pegfilgrastim to treat chemotherapy-related neutropenia, says the report.

Latest news

More from news
Approximately 1 fully matching, plus 23 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...